| |

10 New Clinical Practice Guidelines on Immunotherapy for Mesothelioma

ByHolly Zink

10 New Clinical Practice Guidelines on Immunotherapy for MesotheliomaThe Society for Immunotherapy of Cancer (SITC) organized a multidisciplinary panel of experts to develop new clinical practice guidelines on the use of immunotherapy in mesothelioma treatment.

Immunotherapy is a type of cancer treatment. It uses the patient’s immune system to fight cancer. Immunotherapy has changed lung cancer care in recent years. It can help some patients survive longer. There is a new type of immune treatment called Immune checkpoint inhibitors (ICIs). ICI’s are used to treat patients with mesothelioma.

The use of ICIs to treat mesothelioma tumors has quickly become part of clinical practice. Immune checkpoint inhibitors block mesothelioma’s natural resistance to immune system

Challenges remain on how to identify patients who might benefit from ICIs. A panel of experts recently published universal guidelines for maximal benefit with immunotherapy.

Panel of Experts Develop a Clinical Practice Guideline

The Society for Immunotherapy of Cancer (SITC) organized a multidisciplinary panel of experts to develop a set of guidelines. Their goal was to provide guidance to the oncology community on the use of immunotherapy.

The expert panel reviewed all the published literature. And used their clinical experience to develop recommendations. These guidelines are for healthcare professionals on important aspects of immunotherapeutic treatment. Recommendations include diagnostic testing, treatment planning, and patient quality of life considerations.

These new clinical practice guidelines give guidance to cancer care providers using immunotherapy to treat patients with mesothelioma.

SITC reports that 3,000 new cases are diagnosed in the U.S. each year. Mesothelioma was the primary cause of death for 45,221 persons aged over 25 years from 1999 to 2015.

Ten Panel Recommendations

  1. A tissue biopsy should be used to diagnose mesothelioma. And, the pathology report should include the histologic subtype.
  2. Patients with mesothelioma should consider genetic testing for BAP1 mutation.
  3. Consultation with thoracic surgeons, pulmonologists, radiation oncologists, and medical oncologists should be considered for newly diagnosed mesothelioma patients.
  4. All mesothelioma patients should be offered participation in clinical trials when possible.
  5. Patients with epithelioid subtype mesothelioma should have individualized treatment decisions with combinations of immunotherapy and chemotherapy.
  6. Patients with non-epithelioid subtype mesothelioma should consider nivolumab plus ipilimumab.
  7. Routine PD-L1 testing is not necessary for mesothelioma patients.
  8. Routine TMB testing is also not recommended.
  9. After treatment with nivolumab and ipilimumab, patients should consider platinum-based chemotherapy with pemetrexed.
  10. Patients who have progressed after immunotherapy and chemotherapy should enroll in clinical trials.

Conclusion

The treatment of mesothelioma has improved significantly with the use of immunotherapy. This latest SITC guideline provides new treatment guidance based on the latest data.

These guidelines will be updated as the field continues to develop.

Source:

Govindan, Ramaswamy, Charu Aggarwal, Scott J. Antonia, Marianne Davies, Steven M. Dubinett, Andrea Ferris, Patrick M. Forde et al. “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.” (2022): e003956. https://digitalcommons.wustl.edu/open_access_pubs/11944

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…